Lv Guoqi, Wu Xiuling, Wang Zhengying, Wu Kanglong, Ang Geer, Cui Shulin, Shi Yuqi, Wang Yu, Liu Delong
Department of Otorhinolaryngology Head and Neck Surgery, Dalian Municipal Central Hospital, Dalian, Liaoning, China.
Dalian Medical University, Dalian, Liaoning, China.
Front Oncol. 2022 Dec 27;12:1072474. doi: 10.3389/fonc.2022.1072474. eCollection 2022.
Currently, studies have shown that a high dose of radiotherapy to the throat have various harmful and adverse effects on the patients' laryngeal function, resulting in the development of pneumonia. This study aimed to explore how radiotherapy dose affected the probability of pneumonia following laryngeal cancer surgery.
A retrospective analysis was done on patients diagnosed with laryngeal cancer between 2010 and 2020 and were treated surgically and with postoperative radiotherapy in the same institution. This study included 108 patients in total, 51 of who were in the low-dose group and 57 of whom were in the high-dose group. Age, gender, the location of laryngeal cancer, the presence or absence of lymph node metastasis, and other demographic and clinical characteristics were collected, and the prevalence of postoperative pneumonia was compared between the two groups.
The total prevalence of postoperative pneumonia was 59.3%, but there was a significant difference between the two groups(high-dose group 71.9% VS low-dose group 45.1%; p=0.005). A total of 9.3% (10/108) of the patients had readmission due to severe pneumonia, and the rate of readmission due to pneumonia was significantly different between the two groups (high-dose group 15.8% VS low-dose group 2.0%, p=0.032). Additionally, the high-dose group's prevalence of Dysphagia was significantly higher than the low-dose group's. According to multivariate logistic modeling, high-dose radiation was a risk factor for pneumonia (OR=4.224, 95%CI =1.603-11.131, p=0.004).
Pneumonia risk could increase with radiotherapy doses > 50 Gy in the treatment of laryngeal cancer. Therefore, we recommend that when the radiation dose surpasses 50Gy, doctors should pay particular attention to the lung health of patients with laryngeal cancer.
目前,研究表明,对喉部进行高剂量放疗会对患者的喉功能产生各种有害和不良影响,从而导致肺炎的发生。本研究旨在探讨放疗剂量如何影响喉癌手术后发生肺炎的概率。
对2010年至2020年间在同一机构诊断为喉癌并接受手术及术后放疗的患者进行回顾性分析。本研究共纳入108例患者,其中低剂量组51例,高剂量组57例。收集患者的年龄、性别、喉癌位置、有无淋巴结转移等人口统计学和临床特征,并比较两组术后肺炎的发生率。
术后肺炎的总发生率为59.3%,但两组之间存在显著差异(高剂量组71.9%对低剂量组45.1%;p=0.005)。共有9.3%(10/108)的患者因重症肺炎再次入院,两组因肺炎再次入院的发生率存在显著差异(高剂量组15.8%对低剂量组2.0%,p=0.032)。此外,高剂量组吞咽困难的发生率显著高于低剂量组。根据多因素逻辑模型,高剂量放疗是肺炎的一个危险因素(OR=4.224,95%CI=1.603-11.131,p=0.004)。
在喉癌治疗中,放疗剂量>50Gy时肺炎风险可能增加。因此,我们建议当放疗剂量超过50Gy时,医生应特别关注喉癌患者的肺部健康。